Saw my MO yesterday. I need to make a decision by next week on how to proceed. My personal life is imploding and all I see there is having to sell my house and move to... someplace -- long story, but everything I've tried has come up short. BTW, I live by myself with no close friends and only a very sick relative nearby.
Here's what my MO says:
"Today, I reviewed the result of his recent PSA from 4/1/2022, which increased to 8.16 ng/ml compared to 6.26 ng/ml on 2/1/2022. His testosterone level remained castrated at 16. Then, I reviewed his recent CT studies, which showed a new indeterminate 6 mm groundglass nodule in the right upper lobe; and interval increase in size of a sclerotic lesion within the lower aspect of the left pubic bone. His bone scan showed interval increase in radiotracer activity within the cervical spine and bilateral ribs without new sites of osseous metastatic disease. There is stable osseous metastatic disease within the manubrium, pelvis, right proximal femur, and thoracolumbar spine. Based on these clinical data, he has progressive metastatic castration resistant prostate adenocarcinoma. I recommend him to discontinue enzalutamide today. [I restarted it last August after Prevenge]
For management of progressive metastatic castration resistant prostate adenocarcinoma, I discussed with him the following treatment options.
The first option is to proceed with systemic chemotherapy with docetaxel based on the following data. In the Tax-327 clinical trial, the group who received docetaxel every 3 weeks had a median survival of 18.9 months compared to 16.5 months in the mitoxantrone groups (P=0.009). 45% of the patients in the group with docetaxel every 3 weeks had at least a 50% decreased in the serum PSA compared to 32% of the mitoxantrone group (NEJM 351;15). The main side effects of docetaxel include but not limited to increased risks of bleeding/infection, alopecia, fatigue, nausea, vomiting, tearing of the eyes, nail changes, and peripheral neuropathy. We have provided him written information of docetaxel to review at home.
The second option is to enroll in an ongoing clinical DORA clinical study that evaluates docetaxel with or without Radium-223. I have provided him a written informed consent to review at home.
The third option is to pursue a palliative care approach without initiation of new systemic treatment. The median survival for patients with metastatic castration resistant prostate adenocarcinoma is approximately 2 to 3 years."
I am so overwhelmed trying to deal with Murphy's screwing up my everyday life I just want to sell the house buy a sailboat and sail off into the sunset, but the way things are going the sailboat would sail without me!
Comments welcome
Oncologic History
9/24/14 - Underwent TURP after PSA noted to be 50.6. Biopsy showed Gleason 9 (4+5) prostate adenocarcinoma
8/19/14 - CT abd/pelv showed 4 x 3.5 cm right kidney mass, sclerotic lesions at T12 and left ischium.
9/14/14 - MRI confirmed 3.7 x 3.5 x 4.1 cm cortical mass in right kidney suspicious for RCC
10/3/14 - NM bone scan showed increased uptake C3, T3, T7, T8, T11 vertebrae, left 1st and 5th ribs and left ischium
10/14/14 - Started on lupron and bicalutamide
6/12/15 - Underwent right radical nephrectomy, found to have renal cell carcinoma, papillary type 1, clinical stage I
8/16/16 - PSA noted to rise up to 9.84 ng/ml. Enzalutamide added to Lupron.
12/3/18 - NM bone scan showed improving uptake in cervical, lower thoracic and upper lumbar spine compared to 12/5/17 study. Persistent uptake in the manubrium, T4 and L5 levels.
3/5/19 - MRI thoracic spine showed involvement of multiple thoracic and lumbar vertebral bodies with marrow involvement only, no abnormal signal in spinal cord
3/28/19 - NM bone scan shows uptake predominantly in thoracic and lumbar spine as well as uptake in sternum and shoulders.
1/15/21: CT chest, abdomen and pelvis and bone scan showed progression of osseous metastases.
2/8/21: Underwent CT guided biopsy of right ilium osseous lesion, which showed metastatic prostate adenocarcinoma.
4/7/21: Underwent TURP (for BPH) and bilateral orchiectomy.
4/21/21: Discontinue enzalutamide.
4/22/21 to 5/2021: Completed 3 cycles of provenge.